User profiles for Allan Lawrie

Allan Lawrie

Imperial College London
Verified email at imperial.ac.uk
Cited by 9704

[PDF][PDF] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

…, M Kasanyinga, S Kelly, R Kirk, ML Knight, A Lawrie… - Cell, 2021 - cell.com
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …

[HTML][HTML] Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

…, SJ Wort, WH Ouwehand, N Soranzo, A Lawrie… - Nature …, 2018 - nature.com
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …

[HTML][HTML] T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre …

…, S Dobson, S Adlou, T de Silva, A Lawrie… - The Lancet …, 2022 - thelancet.com
Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …

Pulmonary hypertension in COPD: results from the ASPIRE registry

…, C Billings, L Pollard, JM Wild, A Lawrie… - European …, 2013 - Eur Respiratory Soc
The phenotype and outcome of severe pulmonary hypertension in chronic obstructive pulmonary
disease (COPD) is described in small numbers, and predictors of survival are unknown…

[HTML][HTML] MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension

…, SE Francis, DJ Rowlands, A Lawrie - The Journal of …, 2016 - Am Soc Clin Investig
Loss of the growth-suppressive effects of bone morphogenetic protein (BMP) signaling has
been demonstrated to promote pulmonary arterial endothelial cell dysfunction and induce …

Targeting vascular remodeling to treat pulmonary arterial hypertension

AAR Thompson, A Lawrie - Trends in molecular medicine, 2017 - cell.com
Pulmonary arterial hypertension (PAH) describes a group of conditions with a common
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive …

Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension

…, LS Howard, JSR Gibbs, A Lawrie… - American journal of …, 2013 - atsjournals.org
Rationale: MicroRNAs (miRNAs or miRs) are implicated in the pathogenesis of various
cardiovascular diseases, including pulmonary arterial hypertension (PAH). Objectives: We …

Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro

A Lawrie, AF Brisken, SE Francis, DI Tayler… - Circulation, 1999 - Am Heart Assoc
Background—Restenosis after percutaneous coronary intervention remains a serious
clinical problem. Progress in local gene therapy to prevent restenosis has been hindered by …

Zebrafish as a tractable model of human cardiovascular disease

…, E Kugler, R Wilkinson, A Lawrie… - British Journal of …, 2022 - Wiley Online Library
Mammalian models including non‐human primates, pigs and rodents have been used
extensively to study the mechanisms of cardiovascular disease. However, there is an increasing …

Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension

…, MR Toshner, SJ Wort, JSR Gibbs, A Lawrie… - Circulation, 2017 - Am Heart Assoc
Background: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high
mortality. Methods: We conducted a comprehensive study of plasma metabolites using …